2024-11-18 - Analysis Report
## Johnson & Johnson (JNJ) Stock Review

This report analyzes Johnson & Johnson (JNJ), a multinational corporation that manufactures medical devices, pharmaceuticals, and consumer packaged goods.

**1. Performance vs. S&P 500 (VOO):**

JNJ's cumulative return is 35.02%, significantly underperforming the S&P 500's 123.86% return.  The difference is -88.84%, placing it at the 4.89th percentile of its historical range relative to the S&P 500 (-94.28% to 17.07%).  This indicates considerable underperformance compared to the broader market.  The provided CAGR data shows consistent but declining performance relative to the S&P 500 over the past several years, with recent years showing negative returns.  The beta consistently hovers around 0.7, suggesting a moderate correlation with the market but lower volatility.  Alpha is consistently positive but declining, indicating some degree of outperformance but diminishing in recent years.


**2. Recent Price Movement:**

* **Closing Price:** $154.0
* **5-Day Moving Average:** $153.36
* **20-Day Moving Average:** $158.62
* **60-Day Moving Average:** $161.91

The price is currently below all three moving averages, suggesting a downtrend.

**3. Technical Indicators & Expected Return:**

* **RSI (24.43):**  Indicates the stock is in oversold territory, suggesting potential for a bounce.
* **PPO (-0.42):** Negative value suggests bearish momentum.
* **20-Day Relative Divergence (-2.82):** Shows a recent short-term decline.
* **Expected Return (0.0%):** The expected return is 0%, indicating that no significant outperformance is anticipated relative to the S&P 500 over a long-term investment horizon (2+ years).  This is consistent with the historical underperformance relative to the market.  The given price of $154.02 does not signal a dramatic event (no indication of a sudden jump or drop).

**4. Recent Financial Performance:**

The recent earnings show fluctuating EPS and relatively stable revenue.  A comparison to analyst estimates (not provided) is necessary to determine whether the recent performance is meeting or exceeding expectations.  The significant drop in EPS from Q3 2023 to Q4 2023 needs investigation.  Missing data on analyst forecasts prevents a complete assessment.

| Date       | EPS    | Revenue      |
|------------|--------|--------------|
| 2024-10-23 | 1.12   | $22.47 B     |
| 2024-07-25 | 1.95   | $22.45 B     |
| 2024-05-01 | 1.35   | $21.38 B     |
| 2024-02-16 | 1.68   | $21.39 B     |
| 2023-10-27 | 10.32  | $21.35 B     |


**5. Revenue and Profitability Analysis:**

Consistent and high profit margins are observed, although a dip in Q4 2023 warrants investigation.  ROE shows variability but generally indicates reasonable profitability, though the unusually high ROE in Q3 2023 requires examination. Further analysis is required to understand the drivers of these fluctuations.


**6. News and Recent Issues:**

(This section requires information from sources like Shacknews and Finbold on recent earnings news, analyst opinions, and market outlook for JNJ.  Please provide this information for a complete analysis.)  Lack of this data significantly limits a thorough assessment.

**7. Overall Analysis:**

JNJ has significantly underperformed the S&P 500 over the period examined, despite maintaining high profit margins and reasonable profitability metrics. Recent price action suggests a downtrend, supported by technical indicators. While the RSI indicates oversold conditions, a negative PPO and the recent relative divergence point toward bearish momentum.  The 0% expected return suggests that outperforming the market with JNJ is unlikely in the long term, barring unforeseen positive catalysts.  Crucially, a review of recent news, earnings reports compared to expectations, and analyst opinions is needed to provide a comprehensive outlook.  The substantial drop in Q4 2023 EPS needs explanation.


**8. Recommendations:**

Given the persistent underperformance relative to the S&P 500, the negative technical indicators, and the need for further investigation of recent earnings and news, a cautious approach is advised.  More information is required before forming a definitive investment recommendation.  It is recommended to obtain more data, particularly related to current news, earnings expectations, and analyst sentiment, before making an investment decision.
